Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. van Campen, C. van der Brugeen, P. Trip, K. de Boer, C. Allaart, L. Handoko, F. de Man, H. J. Bogaard, A. Vonk Noordegraaf (Amsterdam, Netherlands). The effects of beta-blocker therapy on systolic and diastolic function in pulmonary arterial hypertension: A randomized controlled trial. Eur Respir J 2014; 44: Suppl. 58, 3422

Member's Comments

No comment yet.

Related content which might interest you: Sildenafil improves heart rate variability, pulmonary hemodynamics and functional status in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Afterload reduction governs improvement in RV systolic function and ventriculo-arterial adaptation in patients with pulmonary arterial hypertension (PAH) undergoing rapid dose escalation of treprostinil Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Randomized, controlled, prospective multicenter study: Training improves peak oxygen consumption and hemodynamics in patients with chronic severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 Beta-blocker therapy nor hyperoxic breathing lowers ventilatory drive in pulmonary arterial hypertension patients Source: International Congress 2014 – Pulmonary hypertension: right ventricular function, exercise and gas exchange Year: 2014 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 LATE-BREAKING ABSTRACT: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Pulmonary arterial hypertension – A single-centre experience Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Atorvastatin in Pulmonary Arterial Hypertension (APATH) study Source: Eur Respir J 2012; 40: 67-74 Year: 2012 Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Exercise-induced pulmonary pressure changes in scleroderma patients – A follow-up study Source: International Congress 2014 – Pulmonary hypertension: right ventricular function, exercise and gas exchange Year: 2014 Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Adherence to pulmonary arterial hypertension targeted therapies Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Pulmonary Function and response to treatment in pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 The different nature of pulmonary vascular resistant and compliance in reduced and preserved ejection fraction heart failure and associated pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricular function, exercise and gas exchange Year: 2014 Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different? Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Pulmonary vascular reactivity in pulmonary hypertension due to left heart disease Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Quality of life of patients with pulmonary arterial hypertension associated with congenital heart disease: The multicenter cross-sectional ACHILLE study Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Nebivolol and pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Non-invasive cardiac output assessment in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014